BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 27743922)

  • 1. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
    Franko J; Shi Q; Meyers JP; Maughan TS; Adams RA; Seymour MT; Saltz L; Punt CJA; Koopman M; Tournigand C; Tebbutt NC; Diaz-Rubio E; Souglakos J; Falcone A; Chibaudel B; Heinemann V; Moen J; De Gramont A; Sargent DJ; Grothey A;
    Lancet Oncol; 2016 Dec; 17(12):1709-1719. PubMed ID: 27743922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Franko J; Shi Q; Goldman CD; Pockaj BA; Nelson GD; Goldberg RM; Pitot HC; Grothey A; Alberts SR; Sargent DJ
    J Clin Oncol; 2012 Jan; 30(3):263-7. PubMed ID: 22162570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
    Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
    Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Peritoneal Metastasis in Stage IV Colorectal Cancer Patients With R0 Resection: A Multicenter, Retrospective Study.
    Arakawa K; Kawai K; Ishihara S; Hata K; Nozawa H; Oba K; Sugihara K; Watanabe T
    Dis Colon Rectum; 2017 Oct; 60(10):1041-1049. PubMed ID: 28891847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
    Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
    Abdel-Rahman O
    Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.
    Goéré D; Glehen O; Quenet F; Guilloit JM; Bereder JM; Lorimier G; Thibaudeau E; Ghouti L; Pinto A; Tuech JJ; Kianmanesh R; Carretier M; Marchal F; Arvieux C; Brigand C; Meeus P; Rat P; Durand-Fontanier S; Mariani P; Lakkis Z; Loi V; Pirro N; Sabbagh C; Texier M; Elias D;
    Lancet Oncol; 2020 Sep; 21(9):1147-1154. PubMed ID: 32717180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
    Sharma V; Sharma A; Raina V; Dabkara D; Mohanti BK; Shukla NK; Pathy S; Thulkar S; Deo SVS; Kumar S; Sahoo RK
    BMC Cancer; 2021 May; 21(1):630. PubMed ID: 34049505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
    Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
    Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distant metastases in colorectal carcinoma: A proposal for a new M1 subclassification.
    Merkel S; Weber K; Croner RS; Golcher H; Göhl J; Agaimy A; Semrau S; Siebler J; Wein A; Hohenberger W; Wittekind C
    Eur J Surg Oncol; 2016 Sep; 42(9):1337-42. PubMed ID: 27160353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
    Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: A Surveillance, Epidemiology, and End Results database analysis.
    Shi T; Huang M; Han D; Tang X; Chen Y; Li Z; Liu C; Xiang D; Wang T; Chen Y; Wang R; Lei Z; Chu X
    Cancer Med; 2019 Apr; 8(4):1930-1940. PubMed ID: 30864303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.